[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0414791A - derivados de purina inibidores da replicação do hiv - Google Patents

derivados de purina inibidores da replicação do hiv

Info

Publication number
BRPI0414791A
BRPI0414791A BRPI0414791-0A BRPI0414791A BRPI0414791A BR PI0414791 A BRPI0414791 A BR PI0414791A BR PI0414791 A BRPI0414791 A BR PI0414791A BR PI0414791 A BRPI0414791 A BR PI0414791A
Authority
BR
Brazil
Prior art keywords
formula
radical
purine derivatives
hiv replication
compound
Prior art date
Application number
BRPI0414791-0A
Other languages
English (en)
Inventor
Paul Adriaan Jan Janssen
Marc Rene De Jonge
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Jan Heeres
Hendrik Maarten Vinkers
Ruben Gerardus George Leenders
Dirk Alfons Leo Vandenput
Paulus Joannes Lewi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0414791A publication Critical patent/BRPI0414791A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE PURINA INIBIDORES DA REPLICAçãO DO HIV". A presente invenção diz respeito ao uso de um composto de fórmula (I) para a fabricação de um medicamento para a prevenção ou o tratamento de infecção por HIV em que o composto de fórmula (I) é um composto de fórmula (I), um N-óxido, um sal de adição farmaceuticamente aceitável, uma amina quaternária ou uma forma estereoquimicamente isomérica deste, em que A e B cada um representa um radical de fórmula (a) ou (b) e, em que -C-D- representa um radical bivalente de fórmula -N=CH-NR¬ 17¬-(c-1); ou -NR¬ 17¬-CH=N-(c-2); contanto que quando A representa um radical de fórmula (a) então B representa um radical de fórmula (b) e quando A representa um radical de fórmula (b) então B representa um radical de fórmula (a).
BRPI0414791-0A 2003-09-25 2004-09-21 derivados de purina inibidores da replicação do hiv BRPI0414791A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350659 2003-09-25
PCT/EP2004/052262 WO2005028479A2 (en) 2003-09-25 2004-09-21 Hiv replication inhibiting purine derivatives

Publications (1)

Publication Number Publication Date
BRPI0414791A true BRPI0414791A (pt) 2006-11-21

Family

ID=34354400

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414791-0A BRPI0414791A (pt) 2003-09-25 2004-09-21 derivados de purina inibidores da replicação do hiv

Country Status (19)

Country Link
US (1) US8026245B2 (pt)
EP (1) EP1668011B1 (pt)
JP (1) JP5506751B2 (pt)
KR (1) KR20060121878A (pt)
CN (1) CN100475815C (pt)
AP (1) AP2006003517A0 (pt)
AT (1) ATE500254T1 (pt)
AU (1) AU2004274185B2 (pt)
BR (1) BRPI0414791A (pt)
CA (1) CA2535313C (pt)
DE (1) DE602004031641D1 (pt)
EA (1) EA009734B1 (pt)
ES (1) ES2361835T3 (pt)
IL (1) IL174467A0 (pt)
MX (1) MXPA06002069A (pt)
NO (1) NO20061788L (pt)
TW (1) TW200518758A (pt)
WO (1) WO2005028479A2 (pt)
ZA (1) ZA200602440B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
EP1720877A4 (en) * 2004-03-02 2009-11-04 Neurogen Corp ANALOGUES OF PURINS ARYL SUBSTITUTION
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
SI2135608T1 (sl) 2004-08-25 2012-03-30 Ardea Biosciences Inc S triazolil alfa merkaptoacetanilidi kot inhibitorji reverzne transkriptaze virusa HIV
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
EP2266569A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
JP5108752B2 (ja) * 2005-05-16 2012-12-26 プロメティック・バイオサイエンスィズ・インコーポレーテッド 自己免疫疾患を治療するための化合物とそれら化合物の使用
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008058285A2 (en) * 2006-11-09 2008-05-15 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
CN103058944B (zh) 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物
WO2009079412A2 (en) 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011756A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010017350A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
WO2010129668A1 (en) 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
CN102712642B (zh) 2009-11-12 2015-08-12 霍夫曼-拉罗奇有限公司 N-7取代的嘌呤和吡唑并嘧啶化合物、组合物和使用方法
WO2011094288A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
JP2013518114A (ja) 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリミジンキナーゼ阻害剤
CA2787315A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US20140018379A1 (en) 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
US10016439B2 (en) 2014-01-31 2018-07-10 Ono Pharmaceutical Co., Ltd. Fused imidazole compounds
EP3235799B1 (en) 2014-12-18 2022-02-23 Nissan Chemical Corporation Oxime compound and herbicide
JP7082120B2 (ja) * 2016-10-21 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
EP3870568B1 (en) * 2018-10-25 2023-06-28 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN114805369B (zh) * 2022-05-30 2023-05-16 自贡市第四人民医院(自贡市急救中心) 一种2，6-二取代嘌呤类化合物及制备方法及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
EP0862463A1 (en) 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
IL138669A0 (en) 1998-03-27 2001-10-31 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidine derivatives
UA70966C2 (uk) 1998-11-10 2004-11-15 Янссен Фармацевтика Н.В. Піримідини, що інгібують реплікацію віл
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
IL150594A0 (en) * 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Also Published As

Publication number Publication date
EP1668011B1 (en) 2011-03-02
US20060293330A1 (en) 2006-12-28
EP1668011A2 (en) 2006-06-14
JP4825672B2 (ja) 2011-11-30
WO2005028479A3 (en) 2005-06-16
JP2007506707A (ja) 2007-03-22
WO2005028479A2 (en) 2005-03-31
ZA200602440B (en) 2007-09-26
US8026245B2 (en) 2011-09-27
IL174467A0 (en) 2006-08-01
JP5506751B2 (ja) 2014-05-28
AU2004274185A1 (en) 2005-03-31
TW200518758A (en) 2005-06-16
JP2012006945A (ja) 2012-01-12
EA200600648A1 (ru) 2006-08-25
CA2535313A1 (en) 2005-03-31
KR20060121878A (ko) 2006-11-29
EA009734B1 (ru) 2008-02-28
ATE500254T1 (de) 2011-03-15
MXPA06002069A (es) 2006-05-19
NO20061788L (no) 2006-04-24
AP2006003517A0 (en) 2006-02-28
ES2361835T3 (es) 2011-06-22
AU2004274185B2 (en) 2009-12-10
DE602004031641D1 (de) 2011-04-14
CN100475815C (zh) 2009-04-08
CN1856496A (zh) 2006-11-01
CA2535313C (en) 2012-07-17

Similar Documents

Publication Publication Date Title
BRPI0414791A (pt) derivados de purina inibidores da replicação do hiv
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
BRPI0407732A (pt) pirimidinas e triazinas inibidoras da replicação de hiv
BRPI0407329A (pt) Derivados de pirimidina para a prevenção de infecção de hiv
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
CY1109681T1 (el) Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
BR0112395A (pt) Derivados de benzotiazol
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
JP2006508953A5 (pt)
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
UY27592A1 (es) Nuevo uso
EA200601654A1 (ru) Ингибиторы интегразы вич
BRPI0407097A (pt) Antagonista do casr
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
BR0111142A (pt) Utilização de derivados de biguanida ou de seus sais farmaceuticamente aceitáveis
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BRPI0406673A (pt) Método para o tratamento ou profilaxia e composição para uso no tratamento ou profilaxia de um ou mais sintomas de uma infecção por herpes viral em um indivìduo, e, uso de uma composição compreendendo um sal citrato e/ou um succinato
PT1156805E (pt) Utilizacao de sistenas piliciclicos de tiazole para a fabricacao de medicamentospara a profilaxia ou o tratamento de obesidade

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]